Raymond James & Associates Royalty Pharma PLC Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Royalty Pharma PLC stock. As of the latest transaction made, Raymond James & Associates holds 805,080 shares of RPRX stock, worth $19.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
805,080
Previous 733,678
9.73%
Holding current value
$19.5 Million
Previous $19.3 Million
17.72%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding RPRX
# of Institutions
413Shares Held
283MCall Options Held
578KPut Options Held
47.5K-
Morgan Stanley New York, NY41.1MShares$997 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA37.6MShares$913 Million0.02% of portfolio
-
Black Rock Inc. New York, NY23MShares$559 Million0.01% of portfolio
-
Baillie Gifford & CO16.1MShares$391 Million0.35% of portfolio
-
Viking Global Investors LP12.1MShares$294 Million1.32% of portfolio
About Royalty Pharma plc
- Ticker RPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 437,139,008
- Market Cap $10.6B
- Description
- Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...